, Volume 22, Issue 4, pp 265–273 | Cite as

Autologous T-Cell Vaccination for Multiple Sclerosis

A Perspective on Progress
Novel Therapeutic Strategies


T-cell vaccination (TCV) is a unique approach to induce immune regulation that may have importance in the treatment of autoimmune diseases, including multiple sclerosis (MS). TCV employs a classic vaccine strategy of injecting an attenuated form of the disease-causing agent — in this case, myelin-reactive T cells — that have been selected and expanded from each MS donor and then re-injected after irradiation to induce protective immunity. This anti-T-cell immunity consistently results in selective deletion or regulation of the targeted pathogenic T cells in vivo. Longitudinal studies have established that TCV is safe and often results in a reduced relapse rate and clinical stability or improvement, at least temporarily, in the majority of treated MS patients. These results lend direct support to the involvement of inflammatory myelin-reactive T cells in the MS disease process. However, these hopeful trends reported in a number of pilot trials await validation in larger proof-of-principle trials that are now in progress.


Multiple Sclerosis Experimental Autoimmune Encephalomyelitis Multiple Sclerosis Patient Myelin Basic Protein Expand Disability Status Scale 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.



The authors wish to thank Ms Eva Niehaus for assistance in preparing the manuscript and acknowledge the support of the Yeshya Horowitz Association (New York, NY, USA), the National Institutes of Health (grant no. NS23221), the Nancy Davis MS Center Without Walls, and the Biomedical Laboratory R&D Service, Department of Veterans Affairs.

Dr Vandenbark has a significant financial interest in Orchestra Therapeutics (formerly the Immune Response Corporation), a company that has a commercial interest in this research and technology. This potential conflict of interest has been reviewed and managed by Oregon Health and Science University and the Veterans Affairs Medical Center (Portland, OR, USA). Dr Abulafia-Lapid has no conflicts of interest that are directly relevant to the content of this review.


  1. 1.
    Raine CS, Scheinberg LC. On the immunopathology of plaque development and repair in multiple sclerosis. J Neuroimmunol 1988; 20: 189–94PubMedCrossRefGoogle Scholar
  2. 2.
    Charcot J-M. Histologie de la sclerose en plaques. Gazette des Hopitaux, Paris 1868; 41: 554–5Google Scholar
  3. 3.
    Trapp BD, Peterson J, Ransohoff RM. Axonal transection in the lesions of multiple sclerosis. N Engl J Med 1998; 338: 278–85PubMedCrossRefGoogle Scholar
  4. 4.
    Steinman L. Multiple sclerosis: a two stage disease. Nat Immunol 2001; 2: 762–5PubMedCrossRefGoogle Scholar
  5. 5.
    Wucherpfennig KW, Strominger JL. Molecular mimicry in T cell-mediated autoimmunity: viral peptides activate human T cell clones specific for myelin basic protein. Cell 1995; 80(5): 695–705PubMedCrossRefGoogle Scholar
  6. 6.
    Hemmer BM, Vergelli B, Gran N, et al. Cutting edge: predictable TCR antigen recognition based on peptide scans leads to the identification of agonist ligands with no sequence homology. J Immunol 1998; 160: 3631–6PubMedGoogle Scholar
  7. 7.
    Vandenbark AA. TCR peptide vaccination in multiple sclerosis: boosting a deficient regulatory network that may involve TCR-specific CD4+CD25+ Treg cells. Curr Drug Targets Inflamm Allergy 2005; 4: 85–94CrossRefGoogle Scholar
  8. 8.
    Lucchinetti C, Brack W, Parisi J, et al. Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann Neurol 2000; 47: 707–17PubMedCrossRefGoogle Scholar
  9. 9.
    Wang C, Gold BG, Kaler LJ, et al. Antigen-specific therapy promotes repair of myelin and axonal damage in established EAE. J Neurochem 2006; 98: 1817–27PubMedCrossRefGoogle Scholar
  10. 10.
    Hellings N, Raus J, Stinissen P. Insights into the immunopathogenesis of multiple sclerosis. Immunol Res 2002; 25: 27–51PubMedCrossRefGoogle Scholar
  11. 11.
    Olsson T, Wang WZ, Hojeberg B, et al. Autoreactive T lymphocytes in multiple sclerosis determined by antigen-induced secretion of interferon-gamma. J Clin Invest 1990; 86: 981–5PubMedCrossRefGoogle Scholar
  12. 12.
    Sun JB, Olsson T, Wang WZ, et al. Autoreactive T and B cells responding to myelin proteolipid protein in multiple sclerosis and controls. Eur J Immunol 1991; 21: 1461–8PubMedCrossRefGoogle Scholar
  13. 13.
    Chou YK, Bourdette DN, Offner H, et al. Frequency of T cells specific for myelin basic protein and myelin proteolipid protein in blood and cerebrospinal fluid in multiple sclerosis. J Neuroimmunol 1992; 38: 105–14PubMedCrossRefGoogle Scholar
  14. 14.
    Ota K, Matsui M, Milford EL, et al. T cell recognition of an immunodominant myelin basic protein epitope in multiple sclerosis. Nature 1990; 346: 183–5PubMedCrossRefGoogle Scholar
  15. 15.
    Trotter JL, Pelfrey CM, Trotter AL, et al. T cell recognition of myelin proteolipid protein and myelin proteolipid protein peptides in the peripheral blood of multiple sclerosis and control subjects. J Neuroimmunol 1998; 84: 172–8PubMedCrossRefGoogle Scholar
  16. 16.
    van Noort JM, vanSechel AC, Bajramovic JJ, et al. The small heat-shock protein a-B-crystallin as candidate autoantigen in multiple sclerosis. Nature 1995; 375: 798–801PubMedCrossRefGoogle Scholar
  17. 17.
    deRosbo NK, Milo R, Lees MB, et al. Peripheral blood lymphocytes respond predominantly to myelin oligodendrocyte glycoprotein. J Clin Invest 1993; 92: 2602–8CrossRefGoogle Scholar
  18. 18.
    Bieganowska KD, Ausubel LJ, Modabber Y, et al. Direct ex vivo analysis of activated fas-sensitive autoreactive T cells in human autoimmune disease. J Exp Med 1997; 185: 1585–94PubMedCrossRefGoogle Scholar
  19. 19.
    Zhang J, Markovic-Plese S, Lacet B, et al. Increased frequency of interleukin 2-responsive T cells specific for myelin basic protein and proteolipid protein in peripheral blood and cerebrospinal fluid of patients with multiple sclerosis. J Exp Med 1994; 179: 973–84PubMedCrossRefGoogle Scholar
  20. 20.
    Wilson DB, Golding AB, Smith RA, et al. Results of a phase I clinical trial of a T-cell receptor peptide vaccine in patients with multiple sclerosis: I, analysis of T-cell receptor utilization in CSF cell populations. J Neuroimmunol 1997; 76: 15–28PubMedCrossRefGoogle Scholar
  21. 21.
    Allegretta M, Nicklas JA, Sriram S, et al. T cells responsive to myelin basic protein in patients with multiple sclerosis. Science 1990; 247: 718–21PubMedCrossRefGoogle Scholar
  22. 22.
    Lodge PA, Johnson C, Sriram S. Frequency of MBP and MBP peptide-reactive T cells in the HPRT mutant T-cell population of MS patients. Neurology 1996; 46: 1410–5PubMedCrossRefGoogle Scholar
  23. 23.
    Trotter JL, Damico CA, Cross AH, et al. HPRT mutant T-cell lines from multiple sclerosis patients recognize myelin proteolipid protein peptides. J Neuroimmunol 1997; 75: 95–103PubMedCrossRefGoogle Scholar
  24. 24.
    Vandenbark AA, Bourdette DN, Whitham R, et al. Episodic changes in T cell frequencies to myelin basic protein in patients with multiple sclerosis. Neurology 1993; 43: 2416–7PubMedCrossRefGoogle Scholar
  25. 25.
    Vandenbark AA, Chou YK, Whitham R, et al. Treatment of multiple sclerosis with T cell receptor peptides: results of a double-blind pilot trial. Nature Med 1996; 2: 1109–15PubMedCrossRefGoogle Scholar
  26. 26.
    Weiner HL, Mackin GA, Matsui M, et al. Double-blind pilot trial of oral tolerization with myelin antigens in multiple sclerosis. Science 1993; 259: 1321–4PubMedCrossRefGoogle Scholar
  27. 27.
    Zhang J, Medaer R, Stinissen P, et al. MHC restricted clonotypic depletion of human myelin basic protein-reactive T cells by T cell vaccination. Science 1993; 261: 1451–4PubMedCrossRefGoogle Scholar
  28. 28.
    Bielekova B, Goodwin B, Richert N, et al. Encephalitogenic potential of the myelin basic protein peptide (amino acids 83-99) in multiple sclerosis: results of a phase II clinical trial with an altered peptide ligand. Nature Med 2000; 6: 1167–75PubMedCrossRefGoogle Scholar
  29. 29.
    Hemmer B, Stefanova I, Vergelli M, et al. Relationships among TCR ligand potency, thresholds for effector function elicitation, and the quality of early signaling events in human T cells. J Immunol 1998; 160: 5807–14PubMedGoogle Scholar
  30. 30.
    Ho HZ, Tiwari JL, Haile RW, et al. HLA-linked and unlinked determinants of multiple sclerosis. Immunogenetics 1982; 15: 509–17PubMedCrossRefGoogle Scholar
  31. 31.
    Francis DA, Batchelor JR, McDonald WI, et al. Multiple sclerosis and HLA-DQw1. Lancet 1986; 1: 211PubMedCrossRefGoogle Scholar
  32. 32.
    Kellar-Wood HF, Wood NW, Holmans P, et al. Multiple sclerosis and the HLA-D region: linkage and association studies. J Neuroimmunol 1995; 58: 183–90PubMedCrossRefGoogle Scholar
  33. 33.
    Hauser SL. T-cell receptor genes: germline polymorphisms and genetic susceptibility to demyelinating diseases. Ann N Y Acad Sci 1995; 756: 233–40PubMedCrossRefGoogle Scholar
  34. 34.
    Wucherpfennig KW, Sette A, Southwood S, et al. Structural requirements for binding of an immunodominant myelin basic protein peptide to DR2 isotypes and for its recognition by human T cell clones. J Exp Med 1994; 179: 279–90PubMedCrossRefGoogle Scholar
  35. 35.
    Noseworthy JH, Gold R, Hartung HP. Treatment of multiple sclerosis: recent trials and future perspectives. Curr Opin Neurol 1999; 12: 279–93PubMedCrossRefGoogle Scholar
  36. 36.
    Polman CH, O’Connor PW, Havrdova E, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2006; 354: 899–910PubMedCrossRefGoogle Scholar
  37. 37.
    Rudick RA, Stuart WH, Calabrese PA, et al. Natalizumab plus Interferon beta-1a for relapsing multiple sclerosis. N Engl J Med 2006; 354: 911–23PubMedCrossRefGoogle Scholar
  38. 38.
    Bar-Or A. Effects of long-term fingolimod therapy on circulating mononuclear cell populations in multiple sclerosis [abstract]. Clin Immunol 2007; 123 Suppl.: 563CrossRefGoogle Scholar
  39. 39.
    Muir M, Lovett-Racke AE, Racke MK. Novel therapeutic strategies targeting the pathogenic T cells in multiple sclerosis. Exp Rev Clin Immunol 2005; 1: 345–55CrossRefGoogle Scholar
  40. 40.
    Ben-Nun A, Wekerle H, Cohen IR. Vaccination against autoimmune encephalomyelitis with T-lymphocyte line cells reactive against myelin basic protein. Nature 1981; 292: 60–1PubMedCrossRefGoogle Scholar
  41. 41.
    Quintana FJ, Cohen IR. Anti-ergotypic immunoregulation. Scand J Immunol 2006; 64: 205–10PubMedCrossRefGoogle Scholar
  42. 42.
    Vandenbark AA, Hashim G, Offner H. Immunization with a synthetic T-cell receptor V-region peptide protects against experimental autoimmune encephalomyelitis. Nature 1989; 341: 541–4PubMedCrossRefGoogle Scholar
  43. 43.
    Howell MD, Winters ST, Olee T, et al. Vaccination against experimental allergic encephalomyelitis with T cell receptor peptides. Science 1989; 246: 668–70PubMedCrossRefGoogle Scholar
  44. 44.
    Zang YCQ, Hong J, Rivera VM, et al. Preferential recognition of TCR hypervariable regions by human anti-idiotypic T cells induced by T cell vaccination. J Immunol 2000; 164: 4011–7PubMedGoogle Scholar
  45. 45.
    Hong J, Zang YCQ, Nie H, et al. CD4+ regulatory T cell responses induced by T cell vaccination in patients with multiple sclerosis. Proc Natl Acad Sci U S A 2006; 103: 5024–9PubMedCrossRefGoogle Scholar
  46. 46.
    Hellings N, Raus J, Stinissen P. T-cell-based immunotherapy in multiple sclerosis: induction of regulatory immune networks by T-cell vaccination. Expert Rev Clin Immunol 2006; 2: 705–16Google Scholar
  47. 47.
    van der Aa A, Hellings N, Medaer R, et al. T cell vaccination in multiple sclerosis patients with autologous CSF-derived activated T cells: results from a pilot study. Clin Exp Immunol 2003; 131: 155–68PubMedCrossRefGoogle Scholar
  48. 48.
    Hafler DA, Cohen I, Benjamin DS, et al. T cell vaccination in multiple sclerosis: a preliminary report. Clin Immunol Immunopathol 1992; 62: 307–13PubMedCrossRefGoogle Scholar
  49. 49.
    Medaer R, Stinissen P, Trayen L, et al. Depletion of myelin-basic-protein autoreactive T cells by T cell vaccination: pilot trial in multiple sclerosis. Lancet 1995; 346: 807–8PubMedCrossRefGoogle Scholar
  50. 50.
    Hermans G, Denzer U, Lohse A, et al. Cellular and humoral immune responses against autoreactive T cells in multiple sclerosis patients after T cell vaccination. J Autoimmunity 1999; 13: 233–46CrossRefGoogle Scholar
  51. 51.
    Zhang JZ, Rivera VM, Tejada-Simon MV, et al. T cell vaccination in multiple sclerosis: results of a preliminary study. J Neurol 2002; 249: 212–8PubMedCrossRefGoogle Scholar
  52. 52.
    Correale J, Lund B, McMillan M, et al. T cell vaccination in secondary progressive multiple sclerosis. J Neuroimmunol 2000; 107: 130–9PubMedCrossRefGoogle Scholar
  53. 53.
    Achiron A, Lavie G, Kishner I, et al. T cell vaccination in multiple sclerosis relapsing-remitting nonresponder patients. Clin Immunol 2004; 113: 155–60PubMedCrossRefGoogle Scholar
  54. 54.
    Stinissen P, Zhang J, Medaer R, et al. Vaccination with autoreactive T cell clones in multiple sclerosis: overview of immunological and clinical data. J Neurosci Res 1996; 45: 500–11PubMedCrossRefGoogle Scholar
  55. 55.
    Hermans G, Medaer R, Raus J, et al. Myelin reactive T cells after T cell vaccination in multiple sclerosis: cytokine profile and depletion by additional immunizations. J Neuroimmunol 2000; 102: 79–84PubMedCrossRefGoogle Scholar
  56. 56.
    Stinissen P, Hermans G, Hellings N, et al. Functional characterization of CD8 anti-clonotypic T cells from MS patients treated with T cell vaccination [abstract]. J Neuroimmunol 1998; 90: A564Google Scholar
  57. 57.
    Zang YCQ, Hong J, Tejada-Simon MV, et al. Th2 immune regulation induced by T cell vaccination in patients with multiple sclerosis. Eur J Immunol 2000; 30: 908–13PubMedCrossRefGoogle Scholar
  58. 58.
    Buenafe AC, Tsaknaridis LJ, Spencer L, et al. Specificity of regulatory CD4+CD25+ T cells for self-T cell receptor determinants. J Neurosci Res 2004; 76: 129–40PubMedCrossRefGoogle Scholar
  59. 59.
    Vandenbark AA, Culbertson NE, Bartholomew RM, et al. Therapeutic vaccination with a trivalent T cell receptor peptide vaccine restores deficient FoxP3 expression and TCR recognition in subjects with multiple sclerosis. Immunology 2007; 123: 66–78PubMedCrossRefGoogle Scholar
  60. 60.
    Hong J, Zang Y, Tejada-Simon MV, et al. Reactivity and regulatory properties of human anti-idiotypic antibodies induced by T cell vaccination. J Immunol 2000; 165: 6858–64PubMedGoogle Scholar

Copyright information

© Adis Data Information BV 2008

Authors and Affiliations

  1. 1.Neuroimmunology Research R&D-31Veterans Affairs Medical CenterPortlandUSA
  2. 2.Department of NeurologyOregon Health & Science UniversityPortlandUSA
  3. 3.Department of Molecular Microbiology and ImmunologyOregon Health & Science UniversityPortlandUSA
  4. 4.Human Biology Research Center (HBRC)Hadassah University HospitalJerusalemIsrael

Personalised recommendations